Moreover, the FLT3+ BP-CML subgroup showed significantly shorter times from 1) diagnosis to death (26.8 vs 206 months) and from 2) BP progression to death (11.7 vs 66 months) than the FLT3− BP-CML subgroup. The gene discussed is FLT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.